Peer-reviewed study published in Journal of Clinical Medicine validates the use of Biobeat’s wrist monitor for advanced noninvasive hemodynamic monitoring in HF patients
PETAH TIKVA, Israel, Jan. 17, 2023 /PRNewswire/ — Biobeat, a global leader in wearable remote patient monitoring solutions for the healthcare continuum, today announced the publication of clinical data demonstrating that the company’s remote patient monitoring wrist device may be utilized for noninvasive wearable multi-parameter monitoring during diuresis in heart failure (HF) patients. The article titled, “Advanced Hemodynamic Monitoring Allows Recognition of Early Response Patterns to Diuresis in Congestive Heart Failure Patients,” was published online on December 21, 2022, in the peer-reviewed Journal of Clinical Medicine.
“Currently, heart failure is a heterogeneous syndrome with no clear guidelines for diuretic administration in heart failure patients’ management at home or in ambulatory care. With an acute condition like congestive heart failure, real-time and continuous monitoring of physiological health parameters is essential to effectively tailor treatment and to improve outcomes,” said Prof. Arik Eisenkraft, VP of Clinical and Regulation at Biobeat. “Data collected from Biobeat’s continuous noninvasive wearable multi-parameter monitoring wrist device provides critical insights for clinicians determining the course of treatment and heart failure patient prognosis. This study marks another step toward the implementation of advanced noninvasive hemodynamic monitoring in heart failure patients using Biobeat’s technologies.”
During the study, 11 physiological parameters were continually collected from 29 HF patients during outpatient intravenous diuresis by Biobeat’s photoplethysmography (PPG)-based wrist monitor and automatically transmitted to a cloud-based data storage, with no personal identifiers or any other protected health information (PHI) included. Efficient and organized storing of data on Biobeat’s remote patient monitoring platform allowed clinicians to analyze health parameters in real-time and retrospectively.
“This peer-reviewed manuscript adds to the growing body of clinical evidence demonstrating the successful application of our devices as a reliable clinical solution for clinicians and patients in both at-home and in-hospital settings,” said Arik Ben Ishay, Founder and CEO of Biobeat. “Given these results in combination with other reported data, we are confident that Biobeat’s technologies will pave the way to a future of seamless, personalized patient management across a broad range of conditions.”
About Biobeat
Biobeat is redefining the way hypertension is diagnosed and managed through a first-of-its-kind, FDA-cleared, cuffless 24-hour blood pressure monitoring platform that delivers accurate, reliable, and comfortable monitoring without disrupting daily life.
Our mission is to ensure that all patients are effectively monitored and managed. By combining 24-hour blood pressure data from our wireless, non-invasive chest patch with patient-reported insights, Biobeat provides a complete view of the patient journey. Clinicians can identify trends, correlate symptoms with vital signs, and make confident, personalized treatment decisions.
Biobeat’s clinically validated platform is setting a new standard in hypertension care, eliminating the discomfort of traditional cuff-based monitoring, reducing white coat syndrome, and replacing fragmented data with a clear, actionable picture of patient health.
For more information follow the link: https://www.prnewswire.com/news-releases/biobeat-demonstrates-prediction-capabilities-of-its-devices-in-heart-failure-patients-under-diuresis-301720612.html?tc=eml_cleartime